A Novel Diet-Phenotype Interaction Affecting Body Weight (FRESH Start)

February 8, 2016 updated by: David S. Ludwig, MD, PhD, Boston Children's Hospital
The primary aim of the study is to examine insulin secretion as an effect modifier of the efficacy of a low-fat vs. low-glycemic load diet for weight loss among overweight/obese young adults in an 18-month, prospectively stratified, multi-center randomized controlled trial.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

In recent years, diets of widely varying composition have been used in the treatment of obesity. While none of these diets has produced consistent, long-term weight loss, some individuals on virtually all types of diets do remarkably well. One explanation for this variation among individuals is differences in motivation and behavior. However, underlying biological differences may also play an important role. Previous work has identified insulin secretion (as quantified by serum insulin concentration at 30 minutes following a standard 75-gram oral glucose load) as an important biological determinant. This randomized-controlled, multi-center trial aims to test the hypothesis that insulin secretion will predict which type of diet will work best for each individual. A total of 160 obese young adults (18 to 40 years) will be assigned to one of two diets: low-fat (60% carbohydrate, 20% fat, 20% protein) or low-glycemic load (45% carbohydrate, 35% fat, 20% protein). Participants will be enrolled at two sites (Children's Hospital Boston or University of North Carolina-Chapel Hill) and assigned to diet groups according to baseline insulin secretion status. The protocol will include an intensive 6-month intervention period and a 12-month follow-up period. Registered dietitians will provide nutrition education and behavioral counseling during group workshops and scheduled telephone calls. In an effort to avoid confounding, close attention will be paid to control for treatment intensity, physical activity prescriptions, and behavioral methods between groups. The primary endpoint will be percent body fat by DXA scan. Secondary endpoints will include cardiovascular and diabetes risk factors. Repeated, 24-hour dietary and physical activity recall interviews will provide process data. Metabolomic profiling and molecular analysis of identified metabolites will be conducted to characterize phenotype and explore potential physiological mechanisms. A successful outcome of this work will inform the practice of "personalized" nutritional therapy, enhancing the ability to select the most efficacious weight loss diet for an individual based on underlying biological differences.

Study Type

Interventional

Enrollment (Actual)

155

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Massachusetts
      • Boston, Massachusetts, United States, 02115
        • Children's Hospital Boston
    • North Carolina
      • Chapel Hill, North Carolina, United States
        • University of North Carolina, Chapel Hill

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria

  • Aged 18 to 40 years.
  • Body mass index (BMI) ≥ 27 kg/m2.
  • Body weight ≤ 300 lb.
  • Access to a working telephone.
  • Clearance in writing from a primary care provider (i.e., physician or nurse practitioner) to rule out pre-existing medical conditions.
  • Willing and able to attend group workshops (for dietary intervention) on specified evenings.

Exclusion Criteria

  • Physician diagnosis of a major medical illness or eating disorder.
  • Chronic use of any medication that may affect study outcomes (e.g., insulin-sensitizing agents).
  • Current smoking (i.e., 1 cigarette in the past week).
  • Physical, mental, or cognitive handicaps that prevent participation.
  • Another member of the family (i.e., first degree relative) or household participating in the study.
  • Planning to relocate from current area of residence during the proposed timeframe for study participation.
  • If female, planning to become pregnant during the 18 months of the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Low glycemic load diet
Active Comparator: Low fat diet

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Percent body fat by dual-energy x-ray absorptiometry (DXA)
Time Frame: 18 months
18 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Triglyceride
Time Frame: 18 months
18 months
HDL cholesterol
Time Frame: 18 months
18 months
LDL cholesterol
Time Frame: 18 months
18 months
C-reactive protein
Time Frame: 18 months
18 months
Plasminogen Activator Inhibitor-1
Time Frame: 18 months
18 months
Fasting blood glucose
Time Frame: 18 months
18 months
Insulin resistance
Time Frame: 18 months
18 months
Blood pressure
Time Frame: 18 months
18 months
Trunk fat
Time Frame: 18 months
18 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serum insulin concentration 30 minutes following a standard 75-gram oral glucose load
Time Frame: 18 months
Effect modification
18 months
Metabolomic profile
Time Frame: 18 months
Effect modification
18 months
Insulin sensitivity
Time Frame: 18 months
Effect modification
18 months
Abdominal-to-total fat ratio
Time Frame: 18 months
Effect modification
18 months
Waist-to-hip ratio
Time Frame: 18 months
Effect modification
18 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Cara B Ebbeling, PhD, Boston Children's Hospital
  • Study Director: Leslie Fischer, PhD, UNC Chapel Hill

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2011

Primary Completion (Actual)

December 1, 2015

Study Completion (Actual)

December 1, 2015

Study Registration Dates

First Submitted

February 22, 2011

First Submitted That Met QC Criteria

February 23, 2011

First Posted (Estimate)

February 25, 2011

Study Record Updates

Last Update Posted (Estimate)

February 9, 2016

Last Update Submitted That Met QC Criteria

February 8, 2016

Last Verified

February 1, 2016

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 10-04-0156

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Dietary counselling

Subscribe